294 related articles for article (PubMed ID: 37066758)
1. Glutathione-Scavenging Nanoparticle-Mediated PROTACs Delivery for Targeted Protein Degradation and Amplified Antitumor Effects.
Liu HJ; Chen W; Wu G; Zhou J; Liu C; Tang Z; Huang X; Gao J; Xiao Y; Kong N; Joshi N; Cao Y; Abdi R; Tao W
Adv Sci (Weinh); 2023 Jun; 10(16):e2207439. PubMed ID: 37066758
[TBL] [Abstract][Full Text] [Related]
2. In situ albumin-binding and esterase-specifically cleaved BRD4-degrading PROTAC for targeted cancer therapy.
Cho H; Jeon SI; Shim MK; Ahn CH; Kim K
Biomaterials; 2023 Apr; 295():122038. PubMed ID: 36787659
[TBL] [Abstract][Full Text] [Related]
3. Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy.
Gao J; Hou B; Zhu Q; Yang L; Jiang X; Zou Z; Li X; Xu T; Zheng M; Chen YH; Xu Z; Xu H; Yu H
Nat Commun; 2022 Jul; 13(1):4318. PubMed ID: 35882867
[TBL] [Abstract][Full Text] [Related]
4. Selective degradation of BRD4 suppresses lung cancer cell proliferation using GSH-responsive PROTAC precursors.
Fan H; Zhou Z; Yu D; Sun J; Wang L; Jia Y; Tian J; Mi W; Sun H
Bioorg Chem; 2023 Nov; 140():106793. PubMed ID: 37683536
[TBL] [Abstract][Full Text] [Related]
5. Nano Proteolysis Targeting Chimeras (PROTACs) with Anti-Hook Effect for Tumor Therapy.
Zhang NY; Hou DY; Hu XJ; Liang JX; Wang MD; Song ZZ; Yi L; Wang ZJ; An HW; Xu W; Wang H
Angew Chem Int Ed Engl; 2023 Sep; 62(37):e202308049. PubMed ID: 37486792
[TBL] [Abstract][Full Text] [Related]
6. Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation.
Chen Y; Tandon I; Heelan W; Wang Y; Tang W; Hu Q
Chem Soc Rev; 2022 Jul; 51(13):5330-5350. PubMed ID: 35713468
[TBL] [Abstract][Full Text] [Related]
7. Hydrogen Peroxide-Inducible PROTACs for Targeted Protein Degradation in Cancer Cells.
Yu D; Fan H; Zhou Z; Zhang Y; Sun J; Wang L; Jia Y; Tian J; Campbell A; Mi W; Sun H
Chembiochem; 2023 Sep; 24(17):e202300422. PubMed ID: 37462478
[TBL] [Abstract][Full Text] [Related]
8. Nanoformulation of BRD4-Degrading PROTAC: Improving Druggability To Target the 'Undruggable' MYC in Pancreatic Cancer.
Minko T
Trends Pharmacol Sci; 2020 Oct; 41(10):684-686. PubMed ID: 32893006
[TBL] [Abstract][Full Text] [Related]
9. Near-Infrared-Activatable PROTAC Nanocages for Controllable Target Protein Degradation and On-Demand Antitumor Therapy.
He Q; Zhou L; Yu D; Zhu R; Chen Y; Song M; Liu X; Liao Y; Ding T; Fan W; Yu W
J Med Chem; 2023 Aug; 66(15):10458-10472. PubMed ID: 37279091
[TBL] [Abstract][Full Text] [Related]
10. Radiation responsive PROTAC nanoparticles for tumor-specific proteolysis enhanced radiotherapy.
Xu M; Yun Y; Li C; Ruan Y; Muraoka O; Xie W; Sun X
J Mater Chem B; 2024 Mar; 12(13):3240-3248. PubMed ID: 38437473
[TBL] [Abstract][Full Text] [Related]
11. Cancer Selective Target Degradation by Folate-Caged PROTACs.
Liu J; Chen H; Liu Y; Shen Y; Meng F; Kaniskan HÜ; Jin J; Wei W
J Am Chem Soc; 2021 May; 143(19):7380-7387. PubMed ID: 33970635
[TBL] [Abstract][Full Text] [Related]
12. Enhanced protein degradation by intracellular delivery of pre-fused PROTACs using lipid-like nanoparticles.
Chen J; Qiu M; Ma F; Yang L; Glass Z; Xu Q
J Control Release; 2021 Feb; 330():1244-1249. PubMed ID: 33234362
[TBL] [Abstract][Full Text] [Related]
13. An overview of PROTACs: a promising drug discovery paradigm.
Liu Z; Hu M; Yang Y; Du C; Zhou H; Liu C; Chen Y; Fan L; Ma H; Gong Y; Xie Y
Mol Biomed; 2022 Dec; 3(1):46. PubMed ID: 36536188
[TBL] [Abstract][Full Text] [Related]
14. Radiotherapy-Triggered Proteolysis Targeting Chimera Prodrug Activation in Tumors.
Yang C; Yang Y; Li Y; Ni Q; Li J
J Am Chem Soc; 2023 Jan; 145(1):385-391. PubMed ID: 36542856
[TBL] [Abstract][Full Text] [Related]
15. MDM2-Based Proteolysis-Targeting Chimeras (PROTACs): An Innovative Drug Strategy for Cancer Treatment.
Vicente ATS; Salvador JAR
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232374
[TBL] [Abstract][Full Text] [Related]
16. Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4.
Lu J; Qian Y; Altieri M; Dong H; Wang J; Raina K; Hines J; Winkler JD; Crew AP; Coleman K; Crews CM
Chem Biol; 2015 Jun; 22(6):755-63. PubMed ID: 26051217
[TBL] [Abstract][Full Text] [Related]
17. Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy.
Moon Y; Jeon SI; Shim MK; Kim K
Pharmaceutics; 2023 Jan; 15(2):. PubMed ID: 36839734
[TBL] [Abstract][Full Text] [Related]
18. Nano-PROTACs: state of the art and perspectives.
Zhong J; Zhao R; Wang Y; Su YX; Lan X
Nanoscale; 2024 Feb; 16(9):4378-4391. PubMed ID: 38305466
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of proteolysis-targeting chimeras (PROTACs) as degraders of glutathione peroxidase 4.
Cai M; Ma F; Hu C; Li H; Cao F; Li Y; Dong J; Qin JJ
Bioorg Med Chem; 2023 Jul; 90():117352. PubMed ID: 37257255
[TBL] [Abstract][Full Text] [Related]
20. Affinity and cooperativity modulate ternary complex formation to drive targeted protein degradation.
Wurz RP; Rui H; Dellamaggiore K; Ghimire-Rijal S; Choi K; Smither K; Amegadzie A; Chen N; Li X; Banerjee A; Chen Q; Mohl D; Vaish A
Nat Commun; 2023 Jul; 14(1):4177. PubMed ID: 37443112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
